[email protected]

Contact UsCustom Services
4basebio

4basebio

4basebio Products

4basebio is a UK-based biotechnology company specializing in the design and manufacture of high-quality synthetic DNA and mRNA products. Headquartered in Cambridge, the company focuses on providing safer, faster, and more scalable alternatives to traditional plasmid-based DNA production methods.

Core Technologies and Offerings

  • Synthetic DNA Manufacturing: 4basebio utilizes an enzyme-driven process to produce linear, plasmid-free DNA constructs. This approach eliminates common contaminants associated with plasmid DNA, such as bacterial endotoxins and antibiotic resistance genes, offering a cleaner and more efficient starting material for gene therapies and vaccines .
  • mRNA Production: Leveraging their synthetic DNA templates, the company provides mRNA synthesis services through an in vitro transcription (IVT) process. This capability supports the development of mRNA-based therapeutics and vaccines .
  • Non-Viral Delivery Systems: 4basebio has developed Hermes™, a proprietary nanoparticle vector system designed for targeted delivery of nucleic acid payloads. Hermes™ combines the safety and efficiency of lipid-based nanoparticles with the specificity of a targeting system, addressing limitations associated with both viral vectors and non-targeted delivery methods .

Applications

The company's synthetic DNA and mRNA products are utilized in various applications, including:

  • Gene Editing: Providing high-purity DNA constructs for CRISPR and other genome editing technologies.
  • Cell and Gene Therapies: Serving as starting materials for the development of therapeutic modalities targeting genetic disorders.
  • Vaccine Development: Supporting the creation of DNA and mRNA vaccines, including those for infectious diseases.
  • AAV Vector Production: Enhancing the production of adeno-associated virus vectors used in gene delivery systems .

Regulatory Milestones

In April 2025, 4basebio received Good Manufacturing Practice (GMP) certification from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This certification authorizes the company to manufacture and supply clinical-grade synthetic DNA, marking a significant milestone in its mission to support the development of cutting-edge therapies .